Latest News

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
07/19/17AcelRx Pharmaceuticals Appoints Raffi Asadorian as Chief Financial Officer
REDWOOD CITY, Calif., July 19, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, today announced the appointment of Raffi Asadorian as chief financial officer, effective August 16, 2017. Mr. Asadorian brings over 25 years of finance, strategy and corporate development experience to AcelRx, most recently as chief financial ... 
Printer Friendly Version
06/01/17AcelRx Pharmaceuticals' ZALVISO Recognized for Innovative Design with Prestigious Red Dot Award
REDWOOD CITY, Calif., June 1, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced that ZALVISO® (sufentanil sublingual tablet system) has been selected for a Red Dot Award in the category of Product Design – Life Sciences and Medicine. The Red Dot Awards in this category are presented to products that display innov... 
Printer Friendly Version
05/31/17AcelRx Pharmaceuticals to Present at Jefferies 2017 Global Healthcare Conference
REDWOOD CITY, Calif., May 31, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today announced that Vincent J. Angotti, Chief Executive Officer, will be presenting at the Jefferies 2017 Global Healthcare Conference. Details of the event are as follows: Jefferies 2017 Healthcare Conference Date: Wednesday, June 7, 2017 Location: Gra... 
Printer Friendly Version
05/08/17AcelRx Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update
- NDA for DSUVIA (sufentanil sublingual tablet, 30 mcg) and MAA for ARX-04 under review at respective agencies - REDWOOD CITY, Calif., May 8, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, today provided a business update and reported financial results for the three months ended March 31, 2017.    Corpo... 
Printer Friendly Version
04/26/17AcelRx Pharmaceuticals to Hold First Quarter 2017 Financial Results Conference Call and Webcast on Monday, May 8th, 2017
REDWOOD CITY, Calif., April 26, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, today announced that it will release First Quarter financial results after market close on Monday, May 8th, 2017. AcelRx management will host an investment-community conference call at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time)... 
Printer Friendly Version
04/13/17AcelRx Pharmaceuticals Reports Publication of Manuscripts Analyzing IV, Transdermal and Sublingual Patient-Controlled Analgesia Systems
REDWOOD CITY, Calif., April 13, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced that Grunenthal, the company's licensee for ZALVISO® in Europe and Australia, has published two analyses of patient-controlled analgesia (PCA) systems in the peer-reviewed journal, Current Medical Research and Opinion. These manuscr... 
Printer Friendly Version
04/06/17AcelRx Pharmaceuticals Presenting Comprehensive DSUVIA Clinical Trial Results at ASRA's Annual Regional Anesthesiology and Acute Pain Medicine Meeting
REDWOOD CITY, Calif., April 6, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced that efficacy and integrated safety results from the DSUVIA™ (formerly ARX-04) clinical program would be presented as an e-poster during the Annual Regional Anesthesiology and Acute Pain Medicine Meeting. The e-poster will be present... 
Printer Friendly Version
03/28/17European Medicines Agency Begins Evaluation of Marketing Application for Sublingual Sufentanil 30 mcg Tablet (ARX-04) for Moderate-to-Severe Acute Pain
CHMP Opinion Expected First Half 2018 REDWOOD CITY, Calif., March 28, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced that the European Medicines Agency (EMA) has notified the company that the ARX-04 (sufentanil sublingual tablet, 30 mcg) Marketing Authorisation Application (MAA) has passed validation, and t... 
Printer Friendly Version
03/17/17AcelRx Pharmaceuticals to Participate at Three Upcoming Investor Events in March and April
REDWOOD CITY, Calif., March 17, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, today announced that Senior Management will be presenting at the Oppenheimer's 27th Annual Healthcare Conference, The MicroCap Conference, and the CF&B European Smallcap Event. Details of the events are as follows: Oppenheime... 
Printer Friendly Version
03/16/17AcelRx Pharmaceuticals Presents Efficacy and Pharmacokinetics of DSUVIA™ at Upcoming Congresses
REDWOOD CITY, Calif., March 16, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, will present data from the DSUVIA™ (sufentanil sublingual tablet, 30 mcg) clinical program at two upcoming medical meetings. On March 16, 2017, during the annual meeting of the American Academy of Pain Medicine, AcelRx will present a poster f... 
Printer Friendly Version
03/02/17AcelRx Pharmaceuticals Reports Fourth Quarter and Year End 2016 Financial Results
- DSUVIA NDA Accepted and PDUFA Date Set for October 12, 2017 - REDWOOD CITY, Calif., March 2, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2016. Corporate and Clinical Highlights During the fourth qua... 
Printer Friendly Version
03/01/17AcelRx Pharmaceuticals to Participate at Two Upcoming Investor Events in March
REDWOOD CITY, Calif., March 1, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, today announced that Timothy E. Morris, Chief Financial Officer, Head of Business Development will be presenting at the 37th Annual Cowen Health Care Conference and the 29th Annual ROTH Conference. Details of the events are as follow... 
Printer Friendly Version
02/27/17AcelRx Pharmaceuticals' New Drug Application for DSUVIA Accepted for Filing with PDUFA Date of October 12, 2017
REDWOOD CITY, Calif., Feb. 27, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced today the U.S. Food and Drug Administration (FDA) has accepted the company's New Drug Application (NDA) under section 505(b)(2) for DSUVIA™ (formerly ARX-04) (sufentanil sublingual tablet, 30 mcg) for the treatment of patients with m... 
Printer Friendly Version
02/23/17AcelRx Pharmaceuticals to Hold Annual 2016 Financial Results Conference Call and Webcast on Thursday, March 2nd, 2017
REDWOOD CITY, Calif., Feb. 23, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced that it will release fourth quarter and yearly financial results after market close on Thursday, March 2nd, 2017. AcelRx management will host an investment-community conference call at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) ... 
Printer Friendly Version
02/16/17AcelRx Pharmaceuticals Appoints Vincent J. Angotti Chief Executive Officer
- Howie Rosen to Continue on Board of Directors - REDWOOD CITY, Calif., Feb. 16, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced that Vincent J. Angotti has been appointed chief executive officer and a member of the company's board of directors, effective Monday, March 6, 2017. Mr. Angotti brings over two de... 
Printer Friendly Version
02/13/17AcelRx Pharmaceuticals Presentation at JAB Burn Symposium Highlights Potential of DSUVIA™ for Use in Burn Victims with Moderate-to-Severe Acute Pain
REDWOOD CITY, Calif., Feb. 13, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced an upcoming podium presentation of comprehensive results from the DSUVIA™ SAP302 study of patients who presented to emergency departments with moderate-to-severe acute pain resulting from trauma or injury, including burns. The presen... 
Printer Friendly Version
02/07/17AcelRx Pharmaceuticals to Participate at Four Upcoming Investor Events in February
REDWOOD CITY, Calif., Feb. 7, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, today announced that Timothy E. Morris, Chief Financial Officer, Head of Business Development will be presenting at the BIO CEO & Investor Conference, 2017 Disruptive Growth & Healthcare Conference, Small Cap Nation Family Off... 
Printer Friendly Version
01/08/17AcelRx Pharmaceuticals Provides Guidance on 2017 Milestones for ARX-04, now known as DSUVIA™ in the United States, for the Treatment of Moderate-to-Severe Acute Pain
· Expected FDA Acceptance of the NDA · Planned Submission of MAA in the EU · Potential Approval and Commercialization in the U.S. REDWOOD CITY, Calif., Jan. 8, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, provided guidance today on 2017 milestones for its lead product, ARX-04, known as DSUVIA™ (sufentanil sublingual tablet, 30 ... 
Printer Friendly Version
01/08/17AcelRx Pharmaceuticals Announces DSUVIA™ as Brand Name for ARX-04 in the United States
REDWOOD CITY, Calif., Jan. 8, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced that the U.S. Food and Drug Administration (FDA) has conditionally accepted the brand name, DSUVIA™ (sufentanil sublingual tablet, 30 mcg), for the company's investigational product candidate, ARX-04. In addition, AcelRx has applied t... 
Printer Friendly Version